Kaplan-Meier estimates of overall survival and leukemia-free survival. (A) OS based on RUNX-1 MT status among SF3B1 MT MDS patients. (B) Leukemia-free survival based on RUNX-1 MT status among SF3B1 MT MDS patients. (C) OS based on SF3B1 mutation status by new proposal IWG criteria. (D) Leukemia-free survival based on SF3B1 mutation status by new proposal IWG criteria.